Fox BioNet Project: LRRK2-002

Primary Objectives:

- Assess the levels of phosphorylated LRRK2 and LRRK2-phosphorylated Rabs, as measures of
LRRK2 kinase activity, in PBMCs and neutrophils from LRRK2 PD, idiopathic PD,
non-manifesting LRRK2 mutation carriers and healthy controls.

- Assess the levels of mtDNA damage in buffy coat from LRRK2 PD, idiopathic PD,
non-manifesting LRRK2 mutation carriers and healthy controls.

- Correlate LRRK2 kinase activity to mtDNA damage in blood from LRRK2 PD, idiopathic-PD,
non-manifesting LRRK2 mutation carriers and healthy controls.

Secondary Objectives:

- To assess the ability of the network to efficiently conduct a study involving biosample
collection for PD research. Efficiency will be assessed using measures of the time taken
to meet specific milestones within the study.

- To assess the ability of the network to collect high quality biospecimens adhering to
agreed-upon, standardized protocols

- To gauge the willingness of participants to participate in subsequent Fox BioNet studies

Inclusion Criteria:

LRRK2 Parkinson Disease (PD) Subjects:

- Patients must have confirmed LRRK2 mutation

- Patients must meet the MDS criteria for Parkinson's disease

- Disease duration: any

- Male or female age 30 years or older at time of PD diagnosis.

Idiopathic PD Subjects:

- Patients must meet the MDS criteria for Parkinson's disease.

- Disease duration: any

- Male or female age 30 years or older at time of PD diagnosis.

Non-manifesting LRRK2 mutation carriers:

- Patients must have confirmed LRRK2 mutation

- Male or female age 30 years or older at Screening.

Control (C) Subjects:

- Male or female age 30 years or older at Screening.

Exclusion Criteria:

LRRK2 Parkinson Disease (PD) Subjects:

- Inability to provide informed consent

- Participation in a blinded clinical trial of any kind or an unblinded trial of an
investigational product that is not currently approved for use in humans.

- Treatment for cancer in the last 5 years.

Idiopathic PD Subjects:

- Inability to provide informed consent

- Participation in a blinded clinical trial of any kind or an unblinded trial of an
investigational product that is not currently approved for use in humans.

- Treatment for cancer in the last 5 years.

Non-manifesting LRRK2 mutation carriers:

- Inability to provide informed consent

- Participation in a blinded clinical trial of any kind or an unblinded trial of an
investigational product that is not currently approved for use in humans.

- Treatment for cancer in the last 5 years.

Control Subjects:

- Inability to provide informed consent

- Participation in a blinded clinical trial of any kind or an unblinded trial of an
investigational product that is not currently approved for use in humans.

- Treatment for cancer in the last 5 years